<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336868">
  <stage>Registered</stage>
  <submitdate>19/05/2011</submitdate>
  <approvaldate>14/06/2011</approvaldate>
  <actrnumber>ACTRN12611000610932</actrnumber>
  <trial_identification>
    <studytitle>Therapeutic effect of saffron on cognitive function  in multiple sclerosis patients</studytitle>
    <scientifictitle>Therapeutic effect of saffron compared to a placebo on cognitive function and depression in definitive multiple sclerosis patients</scientifictitle>
    <utrn>U1111-1121-1162</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple sclerosis</healthcondition>
    <healthcondition>Cognitive dysfunction</healthcondition>
    <healthcondition>Depression</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Multiple sclerosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>saffron capsule  30mg/kg/day for 16 weeks</interventions>
    <comparator>lactose capsule for 16 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Beck-2 depression score</outcome>
      <timepoint>at baseline and 16 weeks after intervention commencement</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>BRB-N memory and cognitive test</outcome>
      <timepoint>at baseline and 16 weeks after intervention commencement</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>possible side effect will be assessed by patient interview:
nausea
drowsiness
change in appetite
allergic reaction</outcome>
      <timepoint>two weeks after intervention commencement</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Definitive diagnosed MS with MC-donald 2010 criteria
3 of 5 memory domain involvement(BRB-N test)
Do not use any treatment for memory function up to 3 month before intervention
Ability to do the test and fill the questionnaire him/herself</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Other cause of cognitive impairment other than MS
MS attack in previous month before intervention
Severe depression according to Beck-2 in the beginning of the intervention
Alcohol or drug abuse among the study
Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomization will be done by person who is not involved in enrolling the patients and write intervention group(A or B) in sealed opaque envelopes after determining its sequence. Thereafter people who are undertaking enrolling, after checking the inclusion and exclusion criteria, open the envelope to determine the intervention group of each patient.</concealment>
    <sequence>Each group(drug/placebo) named A or B by someone who is not involved in enrolling, evaluation and analysis. According to randomization table, sequence of block will be defined.
(Permuted block randomization)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/07/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Tehran University of medical science</primarysponsorname>
    <primarysponsoraddress>poorsina St, Enghelab Sq, tahran, iran
postal/ZIP: 1417613151</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>green plants of life</fundingname>
      <fundingaddress>Num 5, Esfandiari St, vali asr St, Tehran, Iran
postal/ZIP: 1967917191</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Masood Nabavi</sponsorname>
      <sponsoraddress>Mostafa Khomein hospital, Italia ST, Tehran, Iran

Postal/ZIP: 141665185</sponsoraddress>
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Memory dysfunction is a common undesirable symptom in Multiple sclerosis. According to the proved effect of saffron in memory deficit of Alzheimer disease, we hypothesis that it may be helpful for MS patients too.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethic committee of Tehran University of medical science</ethicname>
      <ethicaddress>poorsian St, Enghelab Sq, tahran, iran
postal/ZIP: 1417613151</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Nabavi, seyed masoud</name>
      <address>Mostafa Khomeini Hospital
Vesal St., Italia St.
Tehran
Iran
Postal/ZIP 141665185</address>
      <phone>+982188963122</phone>
      <fax />
      <email>massood@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sadeghi Naini, Mohsen</name>
      <address>Num29, Karimi Alley, Arash Blv, Zafar St.
Tehran
Iran
Postal/ZIP: 1916649411</address>
      <phone>+989124934734</phone>
      <fax />
      <email>dr.msadeghi@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sadeghi Naini, Mohsen</name>
      <address>Num29, Karimi Alley, Arash Blv, Zafar St.
Tehran
Iran
Postal/ZIP: 1916649411</address>
      <phone>+989124934734</phone>
      <fax />
      <email>dr.msadeghi@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>